Treatment and treatment monitoring in children with CAH according to clinical manifestation and gender at age 0–18 years
| Males | Females | ||||
|---|---|---|---|---|---|
| Age (y) | SW (n=21) | NSW (n=13) | SW (n=13) | NSW (n=13) | |
| Results expressed as mean (SD). | |||||
| *Glucocorticoid dose in mg/m2 = (A+B)/m2. A = hydrocortisone dose per day (mg) or cortisone acetate dose per day (mg/1.25); B = fludrocortisone acetate dose (100 μg = 1 mg hydrocortisone effect). | |||||
| †All androstenedione concentrations were compared to reference values for age and sex expressed as treatment scores. They were scored as “normal” (0), “above normal” (1), or “below normal” (−1), indicating adequate treatment, undertreatment, or overtreatment, respectively.16 No distinction was made in the severity of over and under treatment. For each child, the average treatment score was calculated annually. | |||||
| SW, salt wasting; NSW, non-salt wasting. | |||||
| Glucocorticoids* (mg/m2/day) | 0–0.25 | 39.7 (26.1) | 44.9 (35.0) | ||
| 0.25–2 | 17.9 (7.9) | 24.9 (11.2) | |||
| 2–10 | 15.4 (4.6) | 17.9 (6.4) | 15.0 (4.3) | 13.7 (5.9) | |
| 10–18 | 14.4 (3.9) | 14.8 (3.4) | 12.9 (3.7) | 13.2 (5.1) | |
| Androstenedione treatment scores† | 2–6 | 0.08 (0.6) | 0.29 (0.47) | 0.19 (0.6) | 0.19 (0.4) |
| 6–10 10–18 | 0.16 (0.56) 0.13 (0.71) | 0.31 (0.63) 0.22 (0.47) | 0.21 (0.61) 0.35 (0.67) | 0.13 (0.43) 0.21 (0.68) | |